Dr. Amy Yee is the CEO and Founder of Cha Therapeutics and is a tenured full Professor at Tufts University. Cha Therapeutics is the entrepreneurial vehicle to bring her expertise and work to benefit cancer patients. After AB and PHD degrees in Biochemistry (UC Berkeley; UC Davis) and a fellowship in cancer biology (Rockefeller University), she has decades of expertise in cancer biology with emphasis on breast cancers, cell signaling, epigenetics and drug discovery. In her lab, she and her team discovered the lead compound Cha1 as a culmination of years of study into the mechanisms of breast cancer, brain metastases and now hematologic malignancies (AML and MDS). She has been awarded >10M in federal and private grant support and has served extensively as a grant reviewer for numerous federal, private, and international agencies. She has received numerous research awards and reviewer recognition from NIH, American Cancer Society, American Heart Association, Tufts University and from Peking University. With extensive expertise in cancer biology and drug discovery, she launched Cha Therapeutics after acquiring the IP from Tufts University. Recently, she was awarded 3-year non-dilutive funding from Metavivor to begin accelerating Cha1 through IND and into metastatic breast cancer patients.